The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2021Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease
Study Rationale:
Subcellular structures called mitochondria perform many critical activities for brain cells. They generate enormous amounts of energy and remove the calcium that floods into neurons... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021San Antonio Ligand Consortium (SALC)
Study Rationale:
The development of alpha-synuclein and 4-repeat tau (4RT) positron-emission tomography (PET) imaging agents would benefit people with Parkinson’s disease (PD), progressive... -
PIPETTE 4R Tau and Alpha-Synuclein PET Tracer Development, 2021Characterization of PET Tracers for Alpha-synuclein and 4R Tau
Study Rationale:
Parkinson’s disease (PD) is a brain disease characterized by slow movement, rest tremor and stiffness. In most cases the underlying cause is an aggregation of a protein called alpha... -
Target Advancement Program, 2021Pathogenic Mechanisms for Auxilin-mediated Parkinson's Disease
Study Rationale:
Parkinson’s disease (PD) is a prevalent neurodegenerative movement disorder. Several genetic mutations that cause PD have been identified in patients. One such mutation targets... -
Therapeutic Pipeline Program, 2021Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway
Study Rationale:
USP30 is an enzyme which acts in the opposite way to Parkin (PRKN), a gene linked to young-onset Parkinson’s disease (PD). Mutations in the PRKN gene impact mitochondria (the cell’s... -
Therapeutic Pipeline Program, 2021Understand Me for Life: An Intelligibility App for Parkinson's Disease
Study Rationale:
Approximately 90% of people with Parkinson’s develop speech and language problems over the course of the disease, and more than half of these speakers experience problems with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.